Medical information Clinical review pending

Genetic Testing

Parvo Virus B19 RNA Detection Qualitative Test

Detects the presence of Parvovirus B19 RNA in respiratory secretions to diagnose infections caused by this virus, which can lead to conditions like fifth disease or anemia.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question

Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample: Respiratory secretions (e.g., saliva, sputum, nasal mucus), contaminated blood, plasma, or blood products. Confirm specific sample type with the laboratory before booking.
Results: Results are typically available within 36-48 hours. Confirm exact turnaround time with the laboratory before booking.
Preparation: No specific patient preparation is required for this test. However, patients must sign a consent document and provide relevant clinical history.

Test priceKSh 11,560

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Parvo Virus B19 RNA Detection Qualitative Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

Insurer or scheme name & policy / member number
A clinician's request / prescription for the test
Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

Full name *

Mobile number *

+254

Insurer or scheme

Policy / member number (optional)

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

✓Symptoms suggestive of Parvovirus B19 infection (e.g., fever, rash, joint pain, fatigue).
✓Diagnosis in pregnant women with potential exposure.
✓Evaluation of patients with unexplained anemia.
✓Assessment in immunocompromised individuals with relevant symptoms.
✓Investigation of potential outbreaks in specific settings.

In plain language

What this test helps you understand

This test helps confirm or rule out an active Parvovirus B19 infection by detecting the virus's genetic material (RNA). It is particularly useful in diagnosing infections in symptomatic individuals and identifying potential risks in vulnerable populations.

The Parvo Virus B19 RNA Detection Qualitative Test is a diagnostic tool used to identify Parvovirus B19, a virus known to cause various health issues, especially in individuals with weakened immune systems. This test uses a Real-Time PCR method to detect viral RNA in respiratory secretions, offering rapid and accurate results. Understanding if a patient is infected with Parvovirus B19 is crucial for proper medical management and treatment. The virus can cause conditions like fifth disease, anemia, and potentially severe complications in pregnant women and immunocompromised individuals. This test specifically measures the presence of viral RNA in the sample provided, confirming whether the virus is present to allow for timely medical intervention.

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

Speak with us

We check the test and answer your questions before collection.

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

Understand your report

A counselor helps you understand the result and the next steps.

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →

PreparationNo specific patient preparation is required for this test. However, patients must sign a consent document and provide relevant clinical history.

SampleRespiratory secretions (e.g., saliva, sputum, nasal mucus), contaminated blood, plasma, or blood products. Confirm specific sample type with the laboratory before booking.

MethodologyReal-Time Polymerase Chain Reaction (PCR).

PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.

This test detects the presence of viral RNA, indicating an active infection. It does not measure the level of virus (quantitative) or detect past infection (antibodies). A negative result does not completely rule out infection if the sample was collected very early or late in the illness. Confirm with the laboratory before booking.

Read your report

What common result terms mean

TermPlain-language meaning

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.

NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.

VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.

Questions people ask

Frequently asked questions

Parvovirus B19 is a common virus that usually causes mild illness, known as fifth disease, in children. However, it can cause more serious problems in adults, pregnant women, and people with certain medical conditions.

This test helps diagnose an active Parvovirus B19 infection by detecting the virus's RNA. Early diagnosis is important for managing the infection and preventing complications, especially in high-risk individuals.

The test requires a sample of respiratory secretions (like saliva or nasal mucus), or potentially blood, plasma, or blood products depending on the clinical context. Please confirm the required sample type with the laboratory.

Results are reported as positive or negative, indicating whether the viral RNA was detected in the sample. Your doctor will interpret these results in the context of your symptoms and medical history.

Results are typically available within 36 to 48 hours. Please confirm the current turnaround time with the laboratory before booking.

No specific patient preparation is usually required. You will need to sign a consent form and provide your clinical history.

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

ACMG/AMP technical standards for sequence variant interpretation
ClinGen curation and gene–disease validity frameworks where applicable
LOINC-coded reporting for interoperable results
ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

Last updated: September 27, 2026
Medical review: not yet completed
Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Chat on WhatsApp